Short Interest in Fortress Biotech, Inc. (NASDAQ:FBIOP) Decreases By 50.0%

Fortress Biotech, Inc. (NASDAQ:FBIOP) saw a large decline in short interest in the month of October. As of October 31st, there was short interest totalling 100 shares, a decline of 50.0% from the October 15th total of 200 shares. Based on an average daily volume of 20,400 shares, the short-interest ratio is presently 0.0 days.

Fortress Biotech Stock Performance

Shares of NASDAQ FBIOP traded down $0.02 during midday trading on Wednesday, hitting $5.15. The company’s stock had a trading volume of 28,448 shares, compared to its average volume of 17,342. The stock has a fifty day moving average price of $5.50 and a 200 day moving average price of $9.77. Fortress Biotech has a one year low of $4.86 and a one year high of $18.00.

About Fortress Biotech

Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.